6 Results for "

carboxypeptidase A3

" in MedChemExpress (MCE) Product Catalog:
Products (6)

6 Results for "carboxypeptidase A3" in MCE Product Catalog:

3
3 Cited Publications
Cat. No.: HY-70005
CAS No.: 223532-02-3
Synonyms: carboxypeptidase inhibitor
Research Areas:  

Inflammation/Immunology

CPA inhibitor (Compound 5) (Carboxypeptidase inhibitor) is an orally active competitive carboxypeptidase A (CPA) inhibitor with a Ki value of 0.32 μM. CPA inhibitor blocks the activity of carboxypeptidase A3 (CPA3). CPA activator activates the Wnt/Lrp6/β-catenin signaling pathway. CPA inhibitor reduces epithelial damage. CPA inhibitor is applicable to research related to inflammatory bowel disease, including ulcerative colitis and Crohn's disease .
loading...
    loading...
Cat. No.: HY-114118S
Semaglutide-d8 is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
Cat. No.: HY-114118S1
Semaglutide-d8 tetraTFA is the deuterium labeled Semaglutide (HY-114118). Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer .
loading...
    loading...
Cat. No.: HY-P702794
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CPA3; carboxypeptidase A3 (Mast Cell); carboxypeptidase A3; Tissue carboxypeptidase A; Mast Cell carboxypeptidase A; MC-CPA
Species:  
Human
Source:  
E. coli
loading...
    loading...
Cat. No.: HY-P702795
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CPA3; carboxypeptidase A3 (Mast Cell); carboxypeptidase A3; Tissue carboxypeptidase A; Mast Cell carboxypeptidase A; MC-CPA
Species:  
Human
Source:  
P. pastoris
loading...
    loading...
Cat. No.: HY-P70078
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CPA4; carboxypeptidase A3; carboxypeptidase A4; CDNA FLJ75086, Highly Similar To Homo Sapiens carboxypeptidase A4, MRNA; CPA3
Species:  
Mouse
Source:  
HEK293
loading...
    loading...